The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients

Gregory de Lissovoy, Neil R. Powe, Robert I. Griffiths, Alan J. Watson, Gerard F Anderson, Joel W. Greer, Robert J. Herbert, Paulw Eggers, Roger A. Milam, Paul K. Whelton

Research output: Contribution to journalArticle

Abstract

Controversy exists as to whether provider organizational characteristics such as profit status and setting are associated with the content of medical care or efficiency with which care is rendered. Following FDA approval of human recombinant erythropoietin (EPO) for use in clinical practice, Medicare approved coverage for beneficiaries in its end stage renal disease program and established a fixed payment per dose. Because cost of EPO administration varied positively with dose, providers could realize larger profit with prescription of smaller doses. We used Medicare claims data to assess EPO use by renal dialysis providers one year after FDA approval (June 1990) as a function of provider ownership (for-profit, not-for-profit, government agency) and setting (hospital-based, free-standing). Mean dose of EPO was 236 units greater (P =0.0001) for not-for-profit freestanding facilities, 593 units greater (P =0.0001) for government facilities, and 555 units greater for not-for-profit hospitals (P =0.0001) than among for-profit freestanding providers. With fixed payment per dose of EPO, for-profit, freestanding providers prescribed EPO more often and administered smaller doses than not-for-profit or government providers, behavior that is consistent with profit maximization.

Original languageEnglish (US)
Pages (from-to)130-140
Number of pages11
JournalMedical Care
Volume32
Issue number2
StatePublished - 1994

Fingerprint

Erythropoietin
Chronic Kidney Failure
profit
Disease
Medicare
Government Agencies
Ownership
Prescriptions
profit maximization
Renal Dialysis
government agency
Costs and Cost Analysis
medical care
chronic illness
medication
coverage
efficiency
costs

Keywords

  • Chronic
  • Economics
  • Erythropoietin
  • Kidney failure
  • Medical
  • Medicare
  • Renal dialysis units

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Nursing(all)
  • Health(social science)
  • Health Professions(all)

Cite this

de Lissovoy, G., Powe, N. R., Griffiths, R. I., Watson, A. J., Anderson, G. F., Greer, J. W., ... Whelton, P. K. (1994). The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Medical Care, 32(2), 130-140.

The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. / de Lissovoy, Gregory; Powe, Neil R.; Griffiths, Robert I.; Watson, Alan J.; Anderson, Gerard F; Greer, Joel W.; Herbert, Robert J.; Eggers, Paulw; Milam, Roger A.; Whelton, Paul K.

In: Medical Care, Vol. 32, No. 2, 1994, p. 130-140.

Research output: Contribution to journalArticle

de Lissovoy, G, Powe, NR, Griffiths, RI, Watson, AJ, Anderson, GF, Greer, JW, Herbert, RJ, Eggers, P, Milam, RA & Whelton, PK 1994, 'The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients', Medical Care, vol. 32, no. 2, pp. 130-140.
de Lissovoy, Gregory ; Powe, Neil R. ; Griffiths, Robert I. ; Watson, Alan J. ; Anderson, Gerard F ; Greer, Joel W. ; Herbert, Robert J. ; Eggers, Paulw ; Milam, Roger A. ; Whelton, Paul K. / The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. In: Medical Care. 1994 ; Vol. 32, No. 2. pp. 130-140.
@article{854737b1177645cebf4814be13afae1d,
title = "The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients",
abstract = "Controversy exists as to whether provider organizational characteristics such as profit status and setting are associated with the content of medical care or efficiency with which care is rendered. Following FDA approval of human recombinant erythropoietin (EPO) for use in clinical practice, Medicare approved coverage for beneficiaries in its end stage renal disease program and established a fixed payment per dose. Because cost of EPO administration varied positively with dose, providers could realize larger profit with prescription of smaller doses. We used Medicare claims data to assess EPO use by renal dialysis providers one year after FDA approval (June 1990) as a function of provider ownership (for-profit, not-for-profit, government agency) and setting (hospital-based, free-standing). Mean dose of EPO was 236 units greater (P =0.0001) for not-for-profit freestanding facilities, 593 units greater (P =0.0001) for government facilities, and 555 units greater for not-for-profit hospitals (P =0.0001) than among for-profit freestanding providers. With fixed payment per dose of EPO, for-profit, freestanding providers prescribed EPO more often and administered smaller doses than not-for-profit or government providers, behavior that is consistent with profit maximization.",
keywords = "Chronic, Economics, Erythropoietin, Kidney failure, Medical, Medicare, Renal dialysis units",
author = "{de Lissovoy}, Gregory and Powe, {Neil R.} and Griffiths, {Robert I.} and Watson, {Alan J.} and Anderson, {Gerard F} and Greer, {Joel W.} and Herbert, {Robert J.} and Paulw Eggers and Milam, {Roger A.} and Whelton, {Paul K.}",
year = "1994",
language = "English (US)",
volume = "32",
pages = "130--140",
journal = "Medical Care",
issn = "0025-7079",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients

AU - de Lissovoy, Gregory

AU - Powe, Neil R.

AU - Griffiths, Robert I.

AU - Watson, Alan J.

AU - Anderson, Gerard F

AU - Greer, Joel W.

AU - Herbert, Robert J.

AU - Eggers, Paulw

AU - Milam, Roger A.

AU - Whelton, Paul K.

PY - 1994

Y1 - 1994

N2 - Controversy exists as to whether provider organizational characteristics such as profit status and setting are associated with the content of medical care or efficiency with which care is rendered. Following FDA approval of human recombinant erythropoietin (EPO) for use in clinical practice, Medicare approved coverage for beneficiaries in its end stage renal disease program and established a fixed payment per dose. Because cost of EPO administration varied positively with dose, providers could realize larger profit with prescription of smaller doses. We used Medicare claims data to assess EPO use by renal dialysis providers one year after FDA approval (June 1990) as a function of provider ownership (for-profit, not-for-profit, government agency) and setting (hospital-based, free-standing). Mean dose of EPO was 236 units greater (P =0.0001) for not-for-profit freestanding facilities, 593 units greater (P =0.0001) for government facilities, and 555 units greater for not-for-profit hospitals (P =0.0001) than among for-profit freestanding providers. With fixed payment per dose of EPO, for-profit, freestanding providers prescribed EPO more often and administered smaller doses than not-for-profit or government providers, behavior that is consistent with profit maximization.

AB - Controversy exists as to whether provider organizational characteristics such as profit status and setting are associated with the content of medical care or efficiency with which care is rendered. Following FDA approval of human recombinant erythropoietin (EPO) for use in clinical practice, Medicare approved coverage for beneficiaries in its end stage renal disease program and established a fixed payment per dose. Because cost of EPO administration varied positively with dose, providers could realize larger profit with prescription of smaller doses. We used Medicare claims data to assess EPO use by renal dialysis providers one year after FDA approval (June 1990) as a function of provider ownership (for-profit, not-for-profit, government agency) and setting (hospital-based, free-standing). Mean dose of EPO was 236 units greater (P =0.0001) for not-for-profit freestanding facilities, 593 units greater (P =0.0001) for government facilities, and 555 units greater for not-for-profit hospitals (P =0.0001) than among for-profit freestanding providers. With fixed payment per dose of EPO, for-profit, freestanding providers prescribed EPO more often and administered smaller doses than not-for-profit or government providers, behavior that is consistent with profit maximization.

KW - Chronic

KW - Economics

KW - Erythropoietin

KW - Kidney failure

KW - Medical

KW - Medicare

KW - Renal dialysis units

UR - http://www.scopus.com/inward/record.url?scp=17044458483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044458483&partnerID=8YFLogxK

M3 - Article

C2 - 8302105

AN - SCOPUS:17044458483

VL - 32

SP - 130

EP - 140

JO - Medical Care

JF - Medical Care

SN - 0025-7079

IS - 2

ER -